cardiotomskСибирский журнал клинической и экспериментальной медициныSiberian Journal of Clinical and Experimental Medicine2713-29272713-265XTSU publishing10.29001/2073-8552-2022-37-4-22-30cardiotomsk-1616Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESМеханизмы развития гипергликемии и способы ее коррекции при новой коронавирусной инфекцииThe mechanisms of hyperglycemia and its management in new coronavirus infectionhttps://orcid.org/0000-0001-5177-846XПетровВ. И.PetrovV. I.

Петров Владимир Иванович, доктор медицинских наук, профессор, академик РАН, заведующий кафедрой клинической фармакологии и интенсивной терапии

400131, Волгоград, пл. Павших Борцов, 1

Vladimir I. Petrov, Dr. Sci. (Med.), Professor, Full Member of the Russian Academy of Sciences, Head of the Department of Clinical Pharmacology and Intensive  Care

1, Pavshikh Bortsov Sq., Volgograd, 400131

brain@sprintnet.ruhttps://orcid.org/0000-0002-7311-4549ШаталоваО. В.ShatalovaO. V.

Шаталова Ольга Викторовна, доктор медицинских наук, профессор кафедры клинической фармакологии и интенсивной терапии

400131, Волгоград, пл. Павших Борцов, 1

Olga V. Shatalova, Dr. Sci. (Med.), Professor, Department of Clinical Pharmacology and Intensive Care

1, Pavshikh Bortsov Sq., Volgograd, 400131

shov_med@mail.ruhttps://orcid.org/0000-0002-5032-384XГлазоваГ. М.GlazovaG. M.

Глазова Ганна Михайловна, аспирант кафедры клинической фармакологии и интенсивной терапии

400131, Волгоград, пл. Павших Борцов, 1

Ganna M. Glazova, Postgraduate Student, Department of Clinical Pharmacology and Intensive Care

1, Pavshikh Bortsov Sq., Volgograd, 400131

ganna.glazova.91@mail.ruВолгоградский государственный медицинский университет Министерства здравоохранения Российской ФедерацииРоссияVolgograd State Medical UniversityRussian Federation2022160120233742230Copyright © Петров В.И., Шаталова О.В., Глазова Г.М., 20232023Петров В.И., Шаталова О.В., Глазова Г.М.Petrov V.I., Shatalova O.V., Glazova G.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sibjcem.ru/jour/article/view/1616

Гипергликемия стала актуальной проблемой при новой коронавирусной инфекции, так как является предиктором тяжелого течения и плохих исходов как у больных сахарным диабетом (СД), так и у больных без диабета. В статье описаны возможные механизмы развития гипергликемии при новой коронавирусной инфекции COVID-19 с учетом особенностей патогенеза и течения заболевания, репродукции SARS-CoV-2, способы коррекции гипергликемии путем назначения различных режимов инсулинотерапии на основании проведенного обзора отечественной и зарубежной литературы.

Hyperglycemia has become an urgent problem in new coronavirus infection as it is a predictor of a severe course and poor outcomes in both diabetic and non-diabetic patients. This article describes possible mechanisms of hyperglycemia development in new coronavirus infection COVID-19 taking into account peculiarities of pathogenesis and course of the disease, reproduction of SARS-CoV-2, and the ways for hyperglycemia correction by administering different insulin therapy regimens based on the review of national and foreign literature.

новая коронавирусная инфекцияCOVID-19SARS-CoV-2гипергликемиямеханизм развитиянарушения углеводного обменаинсулинорезистентностьсахарный диабетгликемический контрольлечениеCOVID-19SARS-CoV-2hyperglycemiamechanismdisorders of carbohydrate metabolisminsulin resistancediabetes mellitushyperglycemia managementtreatmentРабота выполнена при финансовой поддержке гранта ФГБОУ ВО ВолгГМУ Минздрава России. Проект «Особенности фармакологической коррекции гипергликемии у больных COVID-19 и сахарным диабетом 2-го типа».The work was carried out in a framework of research project supported by research grant from Volgograd State Medical University. The project is titled “Specifi c features of pharmacological correction of hyperglycemia in patients with COVID-19 and type 2 diabetes mellitus”ReferencesWHO Coronavirus (COVID-19) Dashboard. URL: https://covid19.who.int/tableWHO Coronavirus (COVID-19) Dashboard. URL: https://covid19.who. int/tableParohan M., Yaghoubi S., Seraji A., Javanbakht M., Sarraf P., Djalali M. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of observational studies. Aging Male. 2020;23(5):1416–1424. DOI: 10.1080/13685538.2020.1774748.Parohan M., Yaghoubi S., Seraji A., Javanbakht M., Sarraf P., Djalali M. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of observational studies. Aging Male. 2020;23(5):1416–1424. DOI: 10.1080/13685538.2020.1774748.Corona G., Pizzocaro A., Vena W., Rastrelli G., Semeraro F., Isidori A. et al. Diabetes is most important cause for mortality in COVID-19 hospitalized patients: Systematic review and meta-analysis. Rev. Endocr. Metab. Disord. 2021;22(2):275–296. DOI: 10.1007/s11154-021-09630-8.Corona G., Pizzocaro A., Vena W., Rastrelli G., Semeraro F., Isidori A. et al. Diabetes is most important cause for mortality in COVID-19 hospitalized patients: Systematic review and meta-analysis. Rev. Endocr. Metab. Disord. 2021;22(2):275–296. DOI: 10.1007/s11154-021-09630-8.Barron E., Bakhai C., Kar P., Weaver A., Bradley D., Ismail H. et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8(10):813–822. DOI: 10.1016/S2213-8587(20)30272-2.Barron E., Bakhai C., Kar P., Weaver A., Bradley D., Ismail H. et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8(10):813–822. DOI: 10.1016/S2213-8587(20)30272-2.Шестакова М.В., Викулова О.К., Исаков М.А., Дедов И.И. Сахарный диабет и COVID-19: анализ клинических исходов по данным Регистра сахарного диабета Российской Федерации. Проблемы Эндокринологии. 2020;66(1):35–46. DOI: 10.14341/probl12458.Shestakova M.V., Vikulova O.K., Isakov M.A., Dedov I.I. Diabetes and COVID-19: analysis of the clinical outcomes according to the data of the Russian diabetes registry. Problems of Endocrinology. 2020;66(1):35–46. (In Russ.).Gerganova A., Assyov Y., Kamenov Z. Stress gyperglycemia, diabetes mellitus and COVID-19 infection: Risk factors, clinical outcomes and post-discharge implications. Frontiers in Clinical Diabetes and Healthcare. 2022. DOI: 10.3389/fcdhc.2022.826006.Gerganova A., Assyov Y., Kamenov Z. Stress gyperglycemia, diabetes mellitus and COVID-19 infection: Risk factors, clinical outcomes and post-discharge implications. Frontiers in Clinical Diabetes and Healthcare. 2022. DOI: 10.3389/fcdhc.2022.826006.Zhu L., She Z., Cheng X., Qin J., Zhang X., Cai J. et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell. Metab. 2020;31(6):1068–1077.e3. DOI: 10.1016/j.cmet.2020.04.021.Zhu L., She Z., Cheng X., Qin J., Zhang X., Cai J. et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell. Metab. 2020;31(6):1068–1077.e3. DOI: 10.1016/j.cmet.2020.04.021.Hafidh K., Abbas S., Khan A., Kazmi T., Nazir Z., Aldaham T. The clinical characteristics and outcomes of COVID-19 infections in patients with diabetes at a tertiary care center in the UAE. Dubai Diabetes and Endocrinol. J. 2020;26(4):158–163. DOI: 10.1159/000512232.Hafidh K., Abbas S., Khan A., Kazmi T., Nazir Z., Aldaham T. The clinical characteristics and outcomes of COVID-19 infections in patients with diabetes at a tertiary care center in the UAE. Dubai Diabetes and Endocrinol. J. 2020;26(4):158–163. DOI: 10.1159/000512232.Dungan K., Braithwaite S., Preiser J. Stress hyperglycaemia. Lancet. 2009;373(9677):1798–1807. DOI: 10.1016/S0140-6736(09)60553-5.Dungan K., Braithwaite S., Preiser J. Stress hyperglycaemia. Lancet. 2009;373(9677):1798–1807. DOI: 10.1016/S0140-6736(09)60553-5.Moghissi E., Korytkowski M., DiNardo M., Einhorn D., Hellman R., Hirsch I. et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32(6):1119–1131. DOI: 10.2337/dc09-9029.Moghissi E., Korytkowski M., DiNardo M., Einhorn D., Hellman R., Hirsch I. et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32(6):1119–1131. DOI: 10.2337/dc09-9029.Lang C., Dobrescu C., Mészáros K. Insulin-mediated glucose uptake by individual tissues during sepsis. Metabolism. 1990;39(10):1096–1107. DOI: 10.1016/0026-0495(90)90172-9.Lang C., Dobrescu C., Mészáros K. Insulin-mediated glucose uptake by individual tissues during sepsis. Metabolism. 1990;39(10):1096–1107. DOI: 10.1016/0026-0495(90)90172-9.Yu K., Pessin J., Czech M. Regulation of insulin receptor kinase by multisite phosphorylation. Biochimie. 1985;67(10–11):1081–1093. DOI: 10.1016/s0300-9084(85)80105-x.Yu K., Pessin J., Czech M. Regulation of insulin receptor kinase by multisite phosphorylation. Biochimie. 1985;67(10–11):1081–1093. DOI: 10.1016/s0300-9084(85)80105-x.Drews G., Debuyser A., Nenquin M., Henquin J. Galanin and epinephrine act on distinct receptors to inhibit insulin release by the same mechanisms including an increase in K+ permeability of the B-cell membrane. Endocrinology. 1990;126(3):1646–1653. DOI: 10.1210/endo-126-3-1646.Drews G., Debuyser A., Nenquin M., Henquin J. Galanin and epinephrine act on distinct receptors to inhibit insulin release by the same mechanisms including an increase in K+ permeability of the B-cell membrane. Endocrinology. 1990;126(3):1646–1653. DOI: 10.1210/endo-126-3-1646.Ishizuka K., Usui I., Kanatani Y., Bukhari A., He J., Fujisaka S. et al. Chronic tumor necrosis factor-alpha treatment causes insulin resistance via insulin receptor substrate-1 serine phosphorylation and suppressor of cytokine signaling-3 induction in 3T3-L1 adipocytes. Endocrinology. 2007;148(6):2994–3003. DOI: 10.1210/en.2006-1702.Ishizuka K., Usui I., Kanatani Y., Bukhari A., He J., Fujisaka S. et al. Chronic tumor necrosis factor-alpha treatment causes insulin resistance via insulin receptor substrate-1 serine phosphorylation and suppressor of cytokine signaling-3 induction in 3T3-L1 adipocytes. Endocrinology. 2007;148(6):2994–3003. DOI: 10.1210/en.2006-1702.Whitcomb B., Pradhan E., Pittas A., Roghmann M., Perencevich E. Impact of admission hyperglycemia on hospital mortality in various intensive care unit populations. Crit. Care Med. 2005;33(12):2772–2777. DOI: 10.1097/01.ccm.0000189741.44071.25.Whitcomb B., Pradhan E., Pittas A., Roghmann M., Perencevich E. Impact of admission hyperglycemia on hospital mortality in various intensive care unit populations. Crit. Care Med. 2005;33(12):2772–2777. DOI: 10.1097/01.ccm.0000189741.44071.25.Zauner A., Nimmerrichter P., Anderwald C., Bischof M., Schiefermeier M., Ratheiser K. et al. Severity of insulin resistance in critically ill medical patients. Metabolism. 2007;56(1):1–5. DOI: 10.1016/j.metabol.2006.08.014.Zauner A., Nimmerrichter P., Anderwald C., Bischof M., Schiefermeier M., Ratheiser K. et al. Severity of insulin resistance in critically ill medical patients. Metabolism. 2007;56(1):1–5. DOI: 10.1016/j.metabol.2006.08.014.Vanhorebeek I., Van den Berghe G. Diabetes of injury: Тovel insights. Endocrinol. Metab. Clin. North. Am. 2006;35(4):859–x. DOI: 10.1016/j.ecl.2006.09.002.Vanhorebeek I., Van den Berghe G. Diabetes of injury: Тovel insights. Endocrinol. Metab. Clin. North. Am. 2006;35(4):859–x. DOI: 10.1016/j.ecl.2006.09.002.Schetz M., Vanhorebeek I., Wouters P., Wilmer A., Van den Berghe G. Tight blood glucose control is renoprotective in critically ill patients. J. Am. Soc. Nephrol. 2008;19(3):571–578. DOI: 10.1681/ASN.2006101091.Schetz M., Vanhorebeek I., Wouters P., Wilmer A., Van den Berghe G. Tight blood glucose control is renoprotective in critically ill patients. J. Am. Soc. Nephrol. 2008;19(3):571–578. DOI: 10.1681/ASN.2006101091.Weir G., Aguayo-Mazzucato C., Bonner-Weir S. β-cell dedifferentiation in diabetes is important, but what is it? Islets. 2013;5(5):233–237. DOI: 10.4161/isl.27494.Weir G., Aguayo-Mazzucato C., Bonner-Weir S. β-cell dedifferentiation in diabetes is important, but what is it? Islets. 2013;5(5):233–237. DOI: 10.4161/isl.27494.Capes S., Hunt D., Malmberg K., Gerstein H. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet. 2000;355(9206):773– 778. DOI: 10.1016/S0140-6736(99)08415-9.Capes S., Hunt D., Malmberg K., Gerstein H. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet. 2000;355(9206):773– 778. DOI: 10.1016/S0140-6736(99)08415-9.Hamming I., Timens W., Bulthuis M., Lely A., Navis G., van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 2004;203(2):631–637. DOI: 10.1002/path.1570.Hamming I., Timens W., Bulthuis M., Lely A., Navis G., van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 2004;203(2):631–637. DOI: 10.1002/path.1570.Zou X., Chen K., Zou J., Han P., Hao J., Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front. Med. 2020;14(2):185–192. DOI: 10.1007/s11684-020-0754-0.Zou X., Chen K., Zou J., Han P., Hao J., Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front. Med. 2020;14(2):185–192. DOI: 10.1007/s11684-020-0754-0.Zhang H., Li H., Lyu J., Lei X., Li W., Wu G. et al. Specific ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury after 2019-nCoV infection. Int. J. Infect. Dis. 2020;96:19–24. DOI: 10.1016/j.ijid.2020.04.027.Zhang H., Li H., Lyu J., Lei X., Li W., Wu G. et al. Specific ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury after 2019-nCoV infection. Int. J. Infect. Dis. 2020;96:19–24. DOI: 10.1016/j.ijid.2020.04.027.Mine K., Yoshikai Y., Takahashi H., Mori H., Anzai K., Nagafuchi S. Genetic susceptibility of the host in virus-induced diabetes. Microorganisms. 2020;8(8):1133. DOI: 10.3390/microorganisms8081133.Mine K., Yoshikai Y., Takahashi H., Mori H., Anzai K., Nagafuchi S. Genetic susceptibility of the host in virus-induced diabetes. Microorganisms. 2020;8(8):1133. DOI: 10.3390/microorganisms8081133.Hober D., Sauter P. Pathogenesis of type 1 diabetes mellitus: interplay between enterovirus and host. Nat. Rev. Endocrinol. 2010;6(5):279–289. DOI: 10.1038/nrendo.2010.27.Hober D., Sauter P. Pathogenesis of type 1 diabetes mellitus: interplay between enterovirus and host. Nat. Rev. Endocrinol. 2010;6(5):279–289. DOI: 10.1038/nrendo.2010.27.Oshima M., Knoch K., Diedisheim M., Petzold A., Cattan P., Bugliani M. et al. Virus-like infection induces human β cell dedifferentiation. JCI Insight. 2018;3(3). DOI: 10.1172/jci.insight.97732.Oshima M., Knoch K., Diedisheim M., Petzold A., Cattan P., Bugliani M. et al. Virus-like infection induces human β cell dedifferentiation. JCI Insight. 2018;3(3). DOI: 10.1172/jci.insight.97732.Steenblock C., Richter S., Berger I., Barovic M., Schmid J., Schubert U. et al. Viral infiltration of pancreatic islets in patients with COVID-19. Nat. Commun. 2021;12(1):3534. DOI: 10.1038/s41467-021-23886-3.Steenblock C., Richter S., Berger I., Barovic M., Schmid J., Schubert U. et al. Viral infiltration of pancreatic islets in patients with COVID-19. Nat. Commun. 2021;12(1):3534. DOI: 10.1038/s41467-021-23886-3.Meessen-Pinard M., Le Coupanec A., Desforges M., Talbot J. Pivotal role of receptor-interacting protein kinase 1 and mixed lineage kinase domain-like in neuronal cell death induced by the human neuroinvasive coronavirus OC43. J. Virol. 2016;91(1):e01513– e01516. DOI: 10.1128/JVI.01513-16.Meessen-Pinard M., Le Coupanec A., Desforges M., Talbot J. Pivotal role of receptor-interacting protein kinase 1 and mixed lineage kinase domain-like in neuronal cell death induced by the human neuroinvasive coronavirus OC43. J. Virol. 2016;91(1):e01513– e01516. DOI: 10.1128/JVI.01513-16.Wu C., Lidsky P., Xiao Y., Lee I., Cheng R., Nakayama T. et al. SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment. Cell. Metab. 2021;33(8):1565–1576.e5. DOI: 10.1016/j. cmet.2021.05.013.Wu C., Lidsky P., Xiao Y., Lee I., Cheng R., Nakayama T. et al. SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment. Cell. Metab. 2021;33(8):1565–1576.e5. DOI: 10.1016/j. cmet.2021.05.013.Yang L., Han Y., Nilsson-Payant B., Gupta V., Wang P., Duan X. et al. A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids. Cell. Stem. Cell. 2020;27(1):125–136.e7. DOI: 10.1016/j.stem.2020.06.015.Yang L., Han Y., Nilsson-Payant B., Gupta V., Wang P., Duan X. et al. A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids. Cell. Stem. Cell. 2020;27(1):125–136.e7. DOI: 10.1016/j.stem.2020.06.015.Tang X., Uhl S., Zhang T., Xue D., Li B., Vandana J. et al. SARSCoV-2 infection induces beta cell transdifferentiation. Cell. Metab. 2021;33(8):1577–1591.e7. DOI: 10.1016/j.cmet.2021.05.015.Tang X., Uhl S., Zhang T., Xue D., Li B., Vandana J. et al. SARSCoV-2 infection induces beta cell transdifferentiation. Cell. Metab. 2021;33(8):1577–1591.e7. DOI: 10.1016/j.cmet.2021.05.015.Müller J., Gross R., Conzelmann C., Krüger J., Merle U., Steinhart J. et al. SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat. Metab. 2021;3(2):149–165. DOI: 10.1038/s42255-021-00347-1.Müller J., Gross R., Conzelmann C., Krüger J., Merle U., Steinhart J. et al. SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat. Metab. 2021;3(2):149–165. DOI: 10.1038/s42255-021-00347-1.Qadir M., Bhondeley M., Beatty W., Gaupp D., Doyle-Meyers L., Fischer T. et al. SARS-CoV-2 infection of the pancreas promotes thrombofibrosis and is associated with new-onset diabetes. JCI Insight. 2021;6(16):e151551. DOI: 10.1172/jci.insight.151551.Qadir M., Bhondeley M., Beatty W., Gaupp D., Doyle-Meyers L., Fischer T. et al. SARS-CoV-2 infection of the pancreas promotes thrombofibrosis and is associated with new-onset diabetes. JCI Insight. 2021;6(16):e151551. DOI: 10.1172/jci.insight.151551.Kusmartseva I., Wu W., Syed F., Van Der Heide V., Jorgensen M., Joseph P. et al. Expression of SARS-CoV-2 entry factors in the pancreas of normal organ donors and individuals with COVID-19. Cell. Metab. 2020;32(6):1041–1051.e6. DOI: 10.1016/j.cmet.2020.11.005.Kusmartseva I., Wu W., Syed F., Van Der Heide V., Jorgensen M., Joseph P. et al. Expression of SARS-CoV-2 entry factors in the pancreas of normal organ donors and individuals with COVID-19. Cell. Metab. 2020;32(6):1041–1051.e6. DOI: 10.1016/j.cmet.2020.11.005.Unnikrishnan R., Misra A. Diabetes and COVID19: A bidirectional relationship. Nutrition & Diabetes. 2021;11(1):21. DOI: 10.1038/s41387021-00163-2.Unnikrishnan R., Misra A. Diabetes and COVID19: A bidirectional relationship. Nutrition & Diabetes. 2021;11(1):21. DOI: 10.1038/s41387021-00163-2.Cheung N. Steroid-induced hyperglycaemia in hospitalised patients: Does it matter? Diabetologia. 2016;59(12):2507–2509. DOI: 10.1007/ s00125-016-4116-z.Cheung N. Steroid-induced hyperglycaemia in hospitalised patients: Does it matter? Diabetologia. 2016;59(12):2507–2509. DOI: 10.1007/ s00125-016-4116-z.Fong A., Cheung N. The high incidence of steroid-induced hyperglycaemia in hospital. Diabetes Res. Clin. Pract. 2013;99(3):277–280. DOI: 10.1016/j.diabres.2012.12.023.Fong A., Cheung N. The high incidence of steroid-induced hyperglycaemia in hospital. Diabetes Res. Clin. Pract. 2013;99(3):277–280. DOI: 10.1016/j.diabres.2012.12.023.Saand A., Flores M., Kewan T., Alqaisi S., Alwakeel M., Griffiths L. et al. Does inpatient hyperglycemia predict a worse outcome in COVID-19 intensive care unit patients? J. Diabetes. 2021;13(3):253–260. DOI: 10.1111/1753-0407.13137.Saand A., Flores M., Kewan T., Alqaisi S., Alwakeel M., Griffiths L. et al. Does inpatient hyperglycemia predict a worse outcome in COVID-19 intensive care unit patients? J. Diabetes. 2021;13(3):253–260. DOI: 10.1111/1753-0407.13137.Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 2021;384(8):693–704. DOI: 10.1056/nejmoa2021436.Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 2021;384(8):693–704. DOI: 10.1056/nejmoa2021436.Khunti K., Del Prato S., Mathieu C., Kahn S., Gabbay R., Buse J. COVID-19, hyperglycemia, and new-onset diabetes. Diabetes Care. 2021;44(12):2645–2655. DOI: 10.2337/dc21-1318.Khunti K., Del Prato S., Mathieu C., Kahn S., Gabbay R., Buse J. COVID-19, hyperglycemia, and new-onset diabetes. Diabetes Care. 2021;44(12):2645–2655. DOI: 10.2337/dc21-1318.Bonaventura A., Montecucco F. Steroid-induced hyperglycemia: An underdiagnosed problem or clinical inertia? A narrative review. Diabetes Res. Clin. Pract. 2018;139:203–220. DOI: 10.1016/j.diabres.2018.03.006.Bonaventura A., Montecucco F. Steroid-induced hyperglycemia: An underdiagnosed problem or clinical inertia? A narrative review. Diabetes Res. Clin. Pract. 2018;139:203–220. DOI: 10.1016/j.diabres.2018.03.006.Beaupere C., Liboz A., Fève B., Blondeau B., Guillemain G. Molecular mechanisms of glucocorticoid-induced insulin resistance. Int. J. Mol. Sci. 2021;22(2):623. DOI: 10.3390/ijms22020623.Beaupere C., Liboz A., Fève B., Blondeau B., Guillemain G. Molecular mechanisms of glucocorticoid-induced insulin resistance. Int. J. Mol. Sci. 2021;22(2):623. DOI: 10.3390/ijms22020623.Sardu C., D’onofrio N., Balestrieri M., Barbieri M., Rizzo M., Messina V. et al. Outcomes in patients with hyperglycemia affected by COVID-19: Can we do more on glycemic control? Diabetes Care. 2020;43(7):1408– 1415. DOI: 10.2337/dc20-0723.Sardu C., D’onofrio N., Balestrieri M., Barbieri M., Rizzo M., Messina V. et al. Outcomes in patients with hyperglycemia affected by COVID-19: Can we do more on glycemic control? Diabetes Care. 2020;43(7):1408– 1415. DOI: 10.2337/dc20-0723.American Diabetes Association Professional Practice Committee; American Diabetes Association Professional Practice Committee:, Draznin B., Aroda V., Bakris G., Benson G., Brown F., Freeman R. et al. 16. Diabetes сare in the hospital: Standards of medical care in Diabetes-2022. Diabetes Care. 2022;45(1): S244–S253. DOI: 10.2337/dc22-S016.American Diabetes Association Professional Practice Committee; American Diabetes Association Professional Practice Committee:, Draznin B., Aroda V., Bakris G., Benson G., Brown F., Freeman R. et al. 16. Diabetes сare in the hospital: Standards of medical care in Diabetes-2022. Diabetes Care. 2022;45(1): S244–S253. DOI: 10.2337/dc22-S016.Pérez Pérez A., Conthe Gutiérrez P., Aguilar Diosdado M., Bertomeu Martínez V., Galdos Anuncibay P., García De Casasola G. et al. Hospital management of hyperglycemia. Med. Clin. (Barc.). 2009;132(12):465– 475. (In Span.). DOI: 10.1016/j.medcli.2009.02.001.Pérez Pérez A., Conthe Gutiérrez P., Aguilar Diosdado M., Bertomeu Martínez V., Galdos Anuncibay P., García De Casasola G. et al. Hospital management of hyperglycemia. Med. Clin. (Barc.). 2009;132(12):465– 475. (In Span.). DOI: 10.1016/j.medcli.2009.02.001.Umpierrez G., Smiley D., Jacobs S., Peng L., Temponi A., Mulligan P. et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care. 2011;34(2):256–261. DOI: 10.2337/ dc10-1407.Umpierrez G., Smiley D., Jacobs S., Peng L., Temponi A., Mulligan P. et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care. 2011;34(2):256–261. DOI: 10.2337/dc10-1407.Bellido V., Suarez L., Rodriguez M., Sanchez C., Dieguez M., Riestra M. et al. Comparison of basal-bolus and premixed insulin regimens in hospitalized patients with type 2 diabetes. Diabetes Care. 2015;38(12):2211– 2216. DOI: 10.2337/dc15-0160.Bellido V., Suarez L., Rodriguez M., Sanchez C., Dieguez M., Riestra M. et al. Comparison of basal-bolus and premixed insulin regimens in hospitalized patients with type 2 diabetes. Diabetes Care. 2015;38(12):2211– 2216. DOI: 10.2337/dc15-0160.Umpierrez G., Smiley D., Hermayer K., Khan A., Olson D., Newton C. et al. Randomized study comparing a Basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: Basal plus trial. Diabetes Care. 2013;36(8):2169–2174. DOI: 10.2337/dc12-1988.Umpierrez G., Smiley D., Hermayer K., Khan A., Olson D., Newton C. et al. Randomized study comparing a Basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: Basal plus trial. Diabetes Care. 2013;36(8):2169–2174. DOI: 10.2337/dc12-1988.Bueno E., Benitez A., Rufinelli J., Figueredo R., Alsina S., Ojeda A. et al. Basal-bolus regimen with insulin analogues versus human insulin in medical patients with type 2 diabetes: A randomized controlled trial in Latin America. Endocr. Pract. 2015;21(7):807–813. DOI: 10.4158/EP15675.OR.Bueno E., Benitez A., Rufinelli J., Figueredo R., Alsina S., Ojeda A. et al. Basal-bolus regimen with insulin analogues versus human insulin in medical patients with type 2 diabetes: A randomized controlled trial in Latin America. Endocr. Pract. 2015;21(7):807–813. DOI: 10.4158/EP15675.OR.Gentile S., Strollo F., Ceriello A. COVID-19 infection in Italian people with diabetes: Lessons learned for our future (an experience to be used). Diabetes Res. Clin. Pract. 2020;162:108137. DOI: 10.1016/j.diabres.2020.108137.Gentile S., Strollo F., Ceriello A. COVID-19 infection in Italian people with diabetes: Lessons learned for our future (an experience to be used). Diabetes Res. Clin. Pract. 2020;162:108137. DOI: 10.1016/j.diabres.2020.108137.Lopez-Huamanrayme E., Garate-Chirinos D., Espinoza-Morales F., Del-Castillo-Ochoa S., Gomez-Noronha A., Salsavilca-Macavilca E. et al. Association between hyperglycemia treatment and mortality in patients with diabetes and COVID-19 in a Peruvian hospital: A retrospective cohort study. J. Clin. Transl. Endocrinol. 2021;26:100265. DOI: 10.1016/j.jcte.2021.100265.Lopez-Huamanrayme E., Garate-Chirinos D., Espinoza-Morales F., Del-Castillo-Ochoa S., Gomez-Noronha A., Salsavilca-Macavilca E. et al. Association between hyperglycemia treatment and mortality in patients with diabetes and COVID-19 in a Peruvian hospital: A retrospective cohort study. J. Clin. Transl. Endocrinol. 2021;26:100265. DOI: 10.1016/j.jcte.2021.100265.Pichardo-Lowden A., Fan C., Gabbay R. Management of hyperglycemia in the non-intensive care patient: featuring subcutaneous insulin protocols. Endocr. Pract. 2011;17(2):249–260. DOI: 10.4158/EP10220.RA.Pichardo-Lowden A., Fan C., Gabbay R. Management of hyperglycemia in the non-intensive care patient: featuring subcutaneous insulin protocols. Endocr. Pract. 2011;17(2):249–260. DOI: 10.4158/EP10220.RA.Roberts A., James J., Dhatariya K., Agarwal N., Brake J., Brooks C. et al. Joint British Diabetes Societies (JBDS) for Inpatient Care. Management of hyperglycaemia and steroid (glucocorticoid) therapy: A guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. Diabet. Med. 2018;35(8):1011–1017. DOI: 10.1111/dme.13675.Roberts A., James J., Dhatariya K., Agarwal N., Brake J., Brooks C. et al. Joint British Diabetes Societies (JBDS) for Inpatient Care. Management of hyperglycaemia and steroid (glucocorticoid) therapy: A guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. Diabet. Med. 2018;35(8):1011–1017. DOI: 10.1111/dme.13675.Rayman G., Lumb A., Kennon B., Cottrell C., Nagi D., Page E. et al. Dexamethasone therapy in COVID-19 patients: Implications and guidance for the management of blood glucose in people with and without diabetes. Diabet. Med. 2021;38(1):e14378. DOI: 10.1111/dme.14378.Rayman G., Lumb A., Kennon B., Cottrell C., Nagi D., Page E. et al. Dexamethasone therapy in COVID-19 patients: Implications and guidance for the management of blood glucose in people with and without diabetes. Diabet. Med. 2021;38(1):e14378. DOI: 10.1111/dme.14378.Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 16 (18.08.2022).Temporary guidelines “Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)”. Version 16 (08/18/2022). (In Russ.).Стронгин Л.Г., Некрасова Т.А., Беликина Д.В., Корнева К.Г., Петров А.В. Дисгликемия при COVID-19 и сахарном диабете 2 типа: особенности гликемического профиля у госпитализированных пациентов и роль стероид-индуцированных нарушений. Проблемы Эндокринологии. 2022;68(2):56–65. DOI: 10.14341/probl12840.Strongin L.G., Nekrasova T.A., Belikina D.V., Korneva K.G., Petrov A.V. Dysglycemia in COVID-19 and Type 2 Diabetes Mellitus: Peculiarities of the Glycemic Profile in Hospitalized Patients and the Role of Steroid-Induced Disorders. Problems of Endocrinology. 2022;68(2):56–65. (In Russ.). DOI: 10.14341/probl12840.Дедов И.И., Мокрышева Н.Г., Шестакова М.В., Никонова Т.В., Майоров А.Ю., Галстян Г.Р. и др. Контроль гликемии и выбор антигипергликемической терапии у пациентов с сахарным диабетом 2 типа и COVID-19: консенсусное решение совета экспертов Российской ассоциации эндокринологов. Сахарный диабет. 2022;25(1):27–49. DOI: 10.14341/DM12873.Dedov I.I., Mokryisheva N.G., Shestakova M.V., Nikonova T.V., Mayorov A.Yu., Galstyan G.R. et al. Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: A consensus decision of the board of experts of the Russian association of endocrinologists. Diabetes Mellitus. 2022;25(1):27–49. (In Russ.). DOI: 10.14341/DM12873.

The authors declare that there are no conflicts of interest present.